RE:RE:Swirling the tea leaves.Opsens is trading at a market cap of $43 Million vs. 70 or so for PHO. Their quarterly revenues have dropped a lot because of the O&G business and by cleaving that part of the business off into a separate unit, I'm betting they are looking to offload to focus on the coronary product. Given the revenue declines, the O&G business won't be too valuable and might make a decent tuck in acquisition. I'd like to aquire the IP and customer list and have most of the business fold in under PHO rather than taking on a second organization... but hey. I'm just stirring tea leaves!
Cheers!
Grobinso